Determination of Labetalol Hydrochloride by Kinetic Spectrophotometry Using Potassium Permanganate as Oxidant
Nafisur Rahman,1* Nishat Anwar2 Mohammad Kashif3 Md. Nasrul Hoda4 and Habibur Rahman1
1 Analytical Research Division, Department of Chemistry, Aligarh Muslim University, Aligarh (U.P.) 202 002 India. *E–mail: cht17nr_amu@yahoo.com.
2 Anand Engineering College, Keetham Agra U.P. India.
3 National Dope Testing Laboratory, Ministry of Youth Affairs and Sports, Government of India, CGO Complex, New Delhi–110 003, India.
4 Department of Neurology, Medical College of Georgia, 1120 15th Street, Augusta GA 30912 USA.
]]>Received November 13, 2010.
Accepted March 10, 2011.
Abstract
A simple and sensitive kinetic spectrophotometric method was developed for the determination of labetalol (LBT) hydrochloride. The method was based on the kinetic investigation of the oxidation of the drug with alkaline potassium permanganate at room temperature (25 ± 1°C). The increase in absorbance of coloured manganate ions was measured at 605 nm. All experimental variables affecting the development of the colour were investigated and optimized. The initial rate and fixed time (at 6 minute) methods were adopted for determining the drug concentration. The calibration graphs were linear in the concentration ranges of 2–14 μg mL–1 and 1–10 μg mL–1, using the initial rate and fixed time methods, respectively. The method was successfully applied to the determination of labetalol in laboratory made tablets and commercial tablets. The results were validated statistically and through recovery studies.
Keywords: Labetalol hydrochloride, kinetic spectrophotometry, initial rate and fixed time method.
Resumen
Un método simple y sensible de espectrofotometría cinética se desarrolló para la determinación del clorhidrato de labetalol (LBT). El método se basó en la investigación de la cinética de oxidación de la droga con permanganato de potasio alcalino a temperatura ambiente (25 ± 1°C). El aumento de la absorción de iones de manganato coloridos se midió a 605 nm. Se investigaron y optimizaron todas las variables experimentales que afectan al desarrollo del color. Asimismo, se adoptaron la velocidad inicial y el tiempo fijado (a los 6 minutos) de los métodos para la determinación de la concentración del fármaco. Las curvas de calibración fueron lineales en los intervalos de concentración de 2–14 μg mL–1 y 1–10 μg mL–1, haciendo uso de la velocidad inicial y de los tiempos fijados de los métodos, respectivamente. El método se aplicó con éxito a la determinación en el laboratorio de labetalol realizados en tabletas y tabletas comerciales. Los resultados se validaron estadísticamente y mediante estudios de recuperación.
]]> Palabras clave: Clorhidrato de Labetalol, espectrofotometría cinética, velocidad inicial y tiempo fijado del método.
DESCARGAR ARTÍCULO EN FORMATO PDF
References
1. The British Pharmacopoeia, HMSO, London, 2004, Vol. I. [ Links ]
2. The United Sates Pharmacopoeia XXVII. The USP convection Rockville, MD, USA, 2004, 1060–1062 [ Links ]
3. Witek, A.; Hopkala, H.; Matysik, G. Chromatographia 1999, 50, 41–44 [ Links ]
4. Witek, A.; Hopkala, H.; Prazyborowski, L. Chem. Anal. 1998, 43, 817–822 [ Links ]
5. Dakers, J. M.; Boulton, D. W.; Fawcett, J. P. J. Chromatogr. Sect. B. 1997, 704, 215–220 [ Links ]
6. Cenicerors C., Maguregui M. I., Jimenez R. M., Alonso R. M. J. Chromatogr. Sec. B 1998, 705, 97–103 [ Links ]
7. Zhao, H.; Li, H.; Qui, Z. Sepu 1999, 17, 369–371 [ Links ]
8. Magali, D.; Charlotte, D.; Francois, P.; Philippe, D.; Jean–Claude, A. Forensic Sci. Int. 2004, 141, 23–31 [ Links ]
9. Umezawa, H.; Lee, X. P.; Arima, Y.; Hasegawa, C.; Izawa, H.; Kumazawa, T.; Sato, K. Biomed. Chromatogr. 2008, 22, 702–711 [ Links ]
10. Wu, J.; Lord, H. L.; Pawliszyn, J.; Kataoka, H. J. Microcolumn Sep. 2000, 12, 255–266 [ Links ]
11. Gergov, M.; Robson, J. N.; Duchoslov, E.; Ojanpera, I. J. Mass Spectrum. 2000, 35, 912–918 [ Links ]
12. Mario, T.; Georg, O.; Wilhelm, S. Biomed. Chromatogr. 2001, 15, 393–402 [ Links ]
13. Maurer, H. H.; Tenberken, O.; Kratzsch, C. J. Chromatogr. A, 2004, 1058, 169–181 [ Links ]
14. Le Potiera, I.; Tamisier– Karolak, S. L.; Morin, Ph.; Megel, F.; Taverna, M. J. Chromatogr. A 1998, 829, 341–349. [ Links ]
15. Tamisier– Khalendi, S. L.; Stanger, M. A.; Bommart, A. Electrophoresis 1999, 20, 2656–2663. [ Links ]
16. Wang, F.; Khalendi, M. G. Eletrophoresis 1998, 19, 2095–2100. [ Links ]
17. Salonies, H.; Luukkanen, L.; Knutila, R.; J. Pharm. Biomed. Anal. 1989, 7, 1447–1451 [ Links ]
18. Radi, A.; El–Sherif, Z.; Wassel, A. Chem. Papers, 2004, 58, 242–246. [ Links ]
19. Iorio, M. A.; Farina, A. M.; Doldo, A. J. Pharm. Biomed. Anal. 1987, 5, 1–10. [ Links ]
]]>20. Mohamed, M. E. Pharmazie 1983, 38, 784–785. [ Links ]
21. Belal F., Al–Shaboury A., Al–Tamrah A. S. J. Pharm. Biomed. Anal. 2002, 30, 1191–1196. [ Links ]
22. El–Wasseef, D. R.; El–Ashry, S. M.; Abu–El–Enien, M. A.; Moustafa, M. A. A. J. Food Drug Anal. 2006, 14, 133–140. [ Links ]
23. Rahman, N.; Manirul, H. Sk. Int. J. Biomed. Sci. 2008, 4, 140–146. [ Links ]
24. Sane, R. T.; Chandrashekhar, T. G.; Nayak, V. G. Indian Drugs 1986, 23, 565–568. [ Links ]
]]>25. Sastry, C. S. P.; Krishna, D. M. Microchim. Acta. 1996, 122, 87–93. [ Links ]
26. Sastry, C. S. P.; Rao, S. G.; Shrinivas, K. R. Indian Drugs 1998, 35, 594–596. [ Links ]
27. Belal, F.; Al–Shaboury, S.; Al–Tamra, A. S. IL Farmaco 2003, 58, 293–299. [ Links ]
28. Rahman, N.; Rahman, H.; Azmi, S. N. H. J. Chin. Chem. Soc. 2007, 54, 185–196. [ Links ]
29. Salomies, H.; Luukkanen, L.; Knuutila, R. J. Pharm. Biomed. Anal. 1989, 7, 1447–1451. [ Links ]
]]>30. International Conference on Harmonisation, ICH Harmonised Tripartite Guideline–Text on Validation of Analytical Procedures, Fed Regist. 1995; 60:11260. [ Links ]
31. Miller, J. N.; Miller, J. C. Statistics and Chemometrics for Analytical Chemistry; 4th ed., Pearson Education: England, 2000; p 118. [ Links ]
32. Morelli, B. J. Pharm. Biomed. Anal. 2003, 32, 257–267. [ Links ]
33. Hartmann, C.; Verbeke, J. S.; Penninckx, W.; Heyden, Y. V.; Vankeerberghen, P.; Massart, D. L. Anal. Chem. 1995, 67, 4491–4499. [ Links ]
34. Acceptable methods in Drugs Directorate Guidelines, Canada Health Protection Branch, Ministry of National Health and Welfare, Draft, Ottawa, Canada, 1992. [ Links ]
]]>